Viking Therapeutics: Buy, Sell, or Hold?
It has a promising candidate and plenty of cash in hand.
Mindfully Curated
It has a promising candidate and plenty of cash in hand.
A key player in AI is very optimistic about the technology’s potential in healthcare.
This biotech just got clearance to dive into a deep ocean of a market.
Investors who have the patience to think long-term will appreciate this business.
A lot of things need to happen for this speculative coin to reach the $1 mark.
All three companies have vital roles to play in AI integration.
Blackrock is using the blockchain in ways you may not have imagined.
A future change of CEO and an analyst price target cut have impacted the share price today.
Apple is known for the iPhone, but growth and profits are increasingly being made away from hardware sales.
DraftKings isn’t profitable in online betting. The better bet may be one of the companies eating up its marketing dollars.
The fast-casual chain is set up for a great 2024, but valuation should be a concern for investors.
Both Baidu and Toast have significant growth potential.
There are a few positives that are currently under-appreciated.
Solana could continue to soar this year, but only if it addresses two key questions about its future.
From high-flying growth to dividends, there’s something for every investor.
Known more for delivering capital gains, Microsoft and Apple dominated the dividend leaderboard.
The U.S. government will buy hundreds — or possibly thousands — of spy satellites from everyone’s favorite space company.
A long track record of expertise will propel this AI specialist to new heights.
Investors in the chip equipment maker, which is a play on the electric-vehicle (EV) market, were probably most displeased by the fact that the annual guidance cut was the second one in two and a half months.
As authorities crack down on illicit drugs, experts have issued an alert on the use of the synthetic stimulant pentylone, as new research finds a 75% increase in detections across Australia.